Header image

Novo Nordisk Breakfast Symposium: Why Weight? Transforming weight management with Wegovy® (semaglutide 2.4 mg)*

Tracks
Arrhythmia / EP
Mechanisms and Preclinical Discovery
Clinical / Surgical
Heart Failure
Imaging
Multidisciplinary
Paediatrics / Adult Congenital
Other
EHJ / HLC
ANZET
Friday, August 2, 2024
7:15 AM - 8:15 AM
Meeting Room 7

Details

The global obesity epidemic is well established.1 In Australia, approximately 13 million adults were living with overweight or obesity in 2022.2 Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, hypertension, type 2 diabetes and sleep disorders1 and can lead to the development of CVD and CVD mortality independently of other cardiovascular risk factors.1,3 Hear from a panel of local and international experts including Professor Pam Taub, Cardiologist and Professor of Medicine at UC San Diego, alongside Associate Professor Melissa Leung and Professor Gerald Watts. Together they will discuss patient cases and share their clinical experience and practical tips on optimising the use of Wegovy® (semaglutide 2.4 mg)* for managing overweight or obesity in patients with CVD.

Speaker

Agenda Item Image
Prof Melissa Leung
Cardiologist
Liverpool Hospital

Why Weight? Transforming weight management with Wegovy® (semaglutide 2.4 mg)*

7:15 AM - 8:15 AM

Biography

Cardiologist; Clinical Trialist; Biostatistician; Director of Cardiac Imaging & Deputy Director of Clinical Trials at Liverpool Hospital, Sydney.
Agenda Item Image
Prof Pam Taub
Cardiologist / Professor of Medicine
University of California San Diego

Why Weight? Transforming weight management with Wegovy® (semaglutide 2.4 mg)*

7:15 AM - 8:15 AM

Biography

Cardiologist; Professor of Medicine, UC San Diego; Founding Director, STEP Family Foundation Cardiac Rehabilitation and Wellness Center.
Agenda Item Image
Prof Gerald F Watts
Consultant Physician/Professor
Royal Perth Hospital / University of Western Australia

Why Weight? Transforming weight management with Wegovy® (semaglutide 2.4 mg)*

7:15 AM - 8:15 AM

Biography

Head, Cardiometabolic Service, Department of Cardiology and Internal Medicine at Royal Perth Hospital; Senior Consultant Physician; Chair, Familial Hypercholesterolemia Australasia Network.
loading